|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM282101845 |
| 003 |
DE-627 |
| 005 |
20250223075221.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20180221-05
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0940.xml
|
| 035 |
|
|
|a (DE-627)NLM282101845
|
| 035 |
|
|
|a (NLM)29554385
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Conti, Felipe F
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a 36-Month Evaluation of Intravitreous Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.03.2019
|
| 500 |
|
|
|a Date Revised 12.03.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2018, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: In the ASSESS study, patients with neovascular age-related macular degeneration transitioned from other anti-vascular endothelial growth factor therapies to intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI). The purpose was to determine the 36-month outcomes following the change from a fixed 24-month IAI dosing regimen to a routine clinical practice regimen
|
| 520 |
|
|
|a PATIENTS AND METHODS: Patients were treated with a fixed bimonthly regimen for the first 2 years. In the third year, patients were managed according to routine clinical practice
|
| 520 |
|
|
|a RESULTS: A total of 18 patients completed the 36 months and were considered for statistical analyses. At 36 months, a nonsignificant decrease of -37.8 μm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline were observed
|
| 520 |
|
|
|a CONCLUSION: Despite the significant visual and anatomical gains observed in the 2 years of fixed-dosing IAI, there was gradual decline in these improvements when patients were transitioned to a variable regimen. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:179-185.]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a Vascular Endothelial Growth Factor A
|2 NLM
|
| 650 |
|
7 |
|a aflibercept
|2 NLM
|
| 650 |
|
7 |
|a 15C2VL427D
|2 NLM
|
| 650 |
|
7 |
|a Bevacizumab
|2 NLM
|
| 650 |
|
7 |
|a 2S9ZZM9Q9V
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Vascular Endothelial Growth Factor
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a Ranibizumab
|2 NLM
|
| 650 |
|
7 |
|a ZL1R02VT79
|2 NLM
|
| 700 |
1 |
|
|a Silva, Fabiana Q
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Srivastava, Sunil K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ehlers, Justis P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schachat, Andrew P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Singh, Rishi P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 49(2018), 3 vom: 01. März, Seite 179-185
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnas
|
| 773 |
1 |
8 |
|g volume:49
|g year:2018
|g number:3
|g day:01
|g month:03
|g pages:179-185
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20180221-05
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 912 |
|
|
|a GBV_ILN_1127
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 49
|j 2018
|e 3
|b 01
|c 03
|h 179-185
|